Drugs

HTA ID	Drug	Brand	Indication	Assessment status	Date
23028	Mavacamten	Camzyos®	Mavacamten (Camzyos®) is indicated for the treatment of symptomatic (New York Heart Association, NYHA, class II–III), obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.	NCPE assessment ongoing	14th August 2024
-	Melatonin	Circadin®	Prolonged release melatonin (Circadin®) for the short-term treatment of primary insomnia.	Full HTA Assessment	21st October 2008
22048	Melatonin	Slenyto®	For the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome (SMS), where sleep hygiene measures have been insufficient.	Rapid Review Complete	9th August 2022
23067	Melphalan flufenamide	Pepaxti®	Melphalan flufenamide (Pepaxti®) is indicated in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least three years from transplantation.	Rapid Review Complete	15th December 2023
-	Mepolizumab	Nucala®	Is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients.	Assessment Process Complete	1st March 2017
-	Mepolizumab	Nucala®	Mepolizumab 100mg solution in pre-filled pen and mepolizumab 100mg solution in pre-filled syringe are indicated for severe refractory eosinophilic asthma in adults and adolescents aged 12 years and over.	Rapid Review Complete	5th November 2019
20007	Meropenem/vaborbactam	Vaborem®	Is indicated for the treatment of the above infections in adults.	Rapid Review Complete	2nd April 2020
-	Methoxyflurane	Penthrox®	For the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.  It is an inhaled anesthetic with analgesic effects at sub-anesthetic doses.	Rapid Review Complete	18th December 2015
19049	Methyl aminolevulinate	Metvix®	For the treatment of: thin or non-hyperkeratotic and non-pigmented actinic keratoses on the face and scalp, when other therapies are considered less appropriate; superficial and/or nodular basal cell carcinoma unsuitable for other available therapies; and squamous cell carcinoma in situ (Bowen´s disease) when surgical excision is considered less appropriate.	Rapid Review Complete	18th December 2019
-	Midostaurin	Rydapt®	Is indicated in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.	Assessment Process Complete	5th December 2019
-	Midostaurin	Rydapt®	Midostaurin is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL).	Suspended	16th October 2018
-	Mifamurtide	Mepact®	For the treatment of osteosarcoma.	Rapid Review Complete	13th July 2010
-	Migalastat	Galafold®	For the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.	Assessment Process Complete	1st June 2017
-	Mirabegron	Betmiga®	Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.	Rapid Review Complete	12th March 2013
23040	Mirikizumab	Omvoh®	Mirikizumab (Omvoh®) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.	Rapid Review Complete	24th August 2023
-	Modified Release Hydrocortisone	Plenadren®	For the treatment of adrenal insufficiency in adults.	Assessment process complete	1st January 2018
20061	Mogamulizumab	Poteligeo®	For the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy.	NCPE Assessment Process Complete	6th July 2023
21060	Molnupiravir	Lagevrio®	For the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.	Rapid Review Complete	24th December 2021
24002	Momelotinib	Omjjara®	Momelotinib (Omjjara®) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.	Rapid Review Complete	22nd February 2024
21051	Mometasone furoate plus olopatadine	Ryaltris®	Is indicated for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis in adults and adolescents aged 12 years and older.	Rapid Review Complete	22nd December 2021
23023	Mosunetuzumab	Lunsumio®	Mosunetuzumab (Lunsumio®) as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.	NCPE assessment ongoing	18th November 2024
-	Nab-paclitaxel	Abraxane®	In combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinomoa of the pancreas.	Assessment Process Complete	5th September 2014
-	Nalmefene	Selincro®	Is indicated for the reduction of alcohol consumption in those aged ≥18 years with alcohol dependence, who do not require immediate detoxification.	Assessment Process Complete	8th April 2014
-	Naloxegel	Moventig®	Is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).	Rapid Review Complete	13th April 2015
20019	Naloxone	Nyxoid®	Intranasal spray is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings. Nyxoid® is indicated in adults and adolescents aged 14 years and over. Nyxoid® is not a substitute for emergency medical care.	Rapid Review Complete	12th May 2020
-	Naltrexone / bupropion	Mysimba®	Is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥ 18 years) with a BMI of ≥30 kg/m2 (obese) or ≥27 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities.	Assessment Process Complete	9th May 2018
-	Natalizumab	Tysabri®	For the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated.	Full HTA Assessment	27th April 2007
-	Nepafenac	Nevanac®	For the prevention and treatment of postoperative pain and inflammation associated with cataract surgery.	Rapid Review Complete	27th June 2011
19057	Neratinib	Nerlynx®	For the extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.	Assessment Process Complete	12th May 2021
23076	Netarsudil-latanoprost	Roclanda®	Netarsudil-latanoprost is indicated for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient intraocular pressure reduction.	Rapid Review Complete	5th June 2024
-	Netupitant/palonosetron	Akynzeo®	For the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and for prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.	Rapid Review Complete	13th October 2015
-	Nilotinib CML resistant/intolerant to imatinib	Tasigna®	For the treatment of chronic phase CML.	Full HTA Assessment	25th February 2008
-	Nilotinib	Tasigna®	For the newly diagnosed Chronic Phase Philadelpha Chromosone positive CML.	Rapid Review Complete	22nd October 2010
-	Nintedanib	Ofev®	Indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).	Assessment Process Complete	22nd February 2016
20034	Nintedanib	Ofev®	For the treatment of other progressive, chronic fibrosing interstitial lung diseases (PF-ILD) in adults.	Assessment Process Complete	24th June 2021
-	Nintedanib	Vargatef®	Is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy.	Assessment Process Complete	25th March 2016
21004	Niraparib	Zejula®	Is indicated as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.	NCPE Assessment Process Complete	26th September 2022
-	Niraparib	Zejula®	Is indicated as monotherapy for maintenance treatment of adult patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.	Assessment Process Complete	14th August 2019
23032	Niraparib in combination with abiraterone acetate	Akeega®	Niraparib in combination with abiraterone acetate and prednisone/prednisolone is indicated for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.	Rapid Review Complete	20th October 2023
22014	Nirmatrelvir/Ritonavir	Paxlovid®	Is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.	NCPE Assessment Process Complete	20th June 2024
-	Nivolumab	Opdivo®	As monotherapy for the adjuvant treatment of adults with melanoma  with involvement of lymph nodes or metastatic disease who have undergone complete resection.	Assessment Process Complete	17th October 2019
20057	Nivolumab	Opdivo®	As monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine and platinum-based combination chemotherapy.	Rapid Review Complete	13th January 2021
21043	Nivolumab	Opdivo®	Nivolumab as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.	NCPE Assessment Process Complete	20th October 2023
21049	Nivolumab	Opdivo®	Nivolumab is indicated in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first line treatment of adult patients with HER2 negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥5.	NCPE Assessment Process Complete	11th July 2023
-	Nivolumab	Opdivo®	Is licensed for the treatment of advanced renal cell carcinoma after prior therapy in adults	Assessment Process Complete	28th March 2017
-	Nivolumab	Opdivo®	As monotherapy is indicated for the treatment of relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.	Rapid Review Complete	18th January 2017
-	Nivolumab	Opdivo®	For the treatment of squamous cell carcinoma of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy.	Rapid Review Complete	30th May 2017
-	Nivolumab	Opdivo®	Is indicated as for monotherapy treatment for patients diagnosed with unresectable metastatic melanoma. Rapid Review	Assessment Process Complete	18th March 2016
22046	Nivolumab	Opdivo®	Is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression ≥1%, who are at high risk of recurrence after undergoing radical resection of MIUC.	NCPE Assessment Process Complete	21st February 2024
-	Nivolumab	Opdivo®	Is indicated for the treatment of adults with locally advanced or metastatic non-squamous NSCLC after prior chemotherapy.	Assessment Process Complete	12th October 2016